Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2000

01-04-2000 | ORIGINAL ARTICLE

In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy

Authors: Patrice Nony, Jean-Paul Guastalla, Paul Rebattu, Patricia Landais, Michel Lievre, Laurence Bontemps, Roland Itti, Jacques Beaune, Xavier Andre-Fouet, Marc Janier

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2000

Login to get access
Metadata
Title
In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy
Authors
Patrice Nony
Jean-Paul Guastalla
Paul Rebattu
Patricia Landais
Michel Lievre
Laurence Bontemps
Roland Itti
Jacques Beaune
Xavier Andre-Fouet
Marc Janier
Publication date
01-04-2000
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800051005

Other articles of this Issue 5/2000

Cancer Chemotherapy and Pharmacology 5/2000 Go to the issue

ORIGINAL ARTICLE

Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs

ORIGINAL ARTICLE

The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization

SHORT COMMUNICATION

Nasal absorption of ondansetron in rats: an alternative route of drug delivery

ORIGINAL ARTICLE

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

ORIGINAL ARTICLE

Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients

ORIGINAL ARTICLE

P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits